This review offers a comprehensive assessment of synergistic immune checkpoint inhibitor (ICI) strategies and their evolving combinations for cancer immunotherapy, highlighting dual and strategically designed treatment options. It emphasizes essential insights into checkpoint blockade, the tumor microenvironment (TME), and innovative inhibitory and stimulatory targets, including CTLA-4, PD-1/PD-L1, LAG-3, TIM-3, and TIGIT. It discusses preclinical and clinical data demonstrating how combination therapies, such as chemotherapy, radiation, targeted medications, and adoptive cell transfer, can enhance therapeutic responses and circumvent drug resistance. The review systematically outlines important clinical research and regulatory approvals, highlighting improved results in melanoma, non-small cell lung cancer, renal cell carcinoma, and colorectal cancer. A comprehensive assessment of biomarker development, sequencing and timing optimization, and the management of immune-related adverse events is undertaken, in conjunction with novel methodologies such as AI-driven biomarker identification and the impact of the gut microbiome on the efficacy of immune checkpoint inhibitors. The research indicates that the optimal approach to enhance treatment efficacy and precision in cancer immunotherapy is through the implementation of rational combination strategies that address multiple immune evasion mechanisms and incorporate manipulation of the tumor microenvironment. This will improve long-term survival and clinical outcomes across all cancer types.
